Drug Profile
Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences
Alternative Names: Amorfix EP-AD; Disease specific epitope (DSE) monoclonal antibodies; Neurodegenerative disorders monoclonal antibodies - Amorfix Life Sciences; Neurodegenerative disorders vaccines - Amorfix Life SciencesLatest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Amorfix Life Sciences
- Developer ProMIS Neurosciences; University of British Columbia
- Class Diagnostic agents; Vaccines
- Mechanism of Action Immunomodulators; Superoxide dismutase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Neurodegenerative disorders
Highest Development Phases
- Suspended Creutzfeldt-Jakob disease
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis(Diagnosis) in Canada (Parenteral)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in Canada (Parenteral, Injection)
- 28 Mar 2017 Preclinical development in Amyotrophic lateral sclerosis and Alzheimer's disease is ongoing in Canada